Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.

Sec. Adrenal Endocrinology

Volume 16 - 2025 | doi: 10.3389/fendo.2025.1511096

This article is part of the Research Topic Comorbidities of adrenal-related endocrine disorders View all 3 articles

Serum MicroRNAs as peripheral markers of primary aldosteronism

Provisionally accepted
Nikita Makhnov Nikita Makhnov *Fredrik Axling Fredrik Axling Elham Barazeghi Elham Barazeghi Peter Stålberg Peter Stålberg Tobias Åkerström Tobias Åkerström Per Hellman Per Hellman
  • Uppsala University, Uppsala, Sweden

The final, formatted version of the article will be published soon.

    Background: Primary aldosteronism (PA) is the principal cause of secondary hypertension; it leads to significantly elevated cardiovascular morbidity and mortality, but only a fraction of its cases ever get detected, partially due to diagnostic procedures that are difficult to perform and to interpret. More straightforward diagnostic methods are needed. Lateralized, or unilateral PA (uPA), is best treated by surgery. Bilateral PA (bPA) is treated medically.Aim: The aim of our study was to explore microRNA (miRNA) in peripheral blood as markers of PA, uPA and bPA.Methods: In groups of subjects with primary hypertension (HT, n = 11), bPA (n = 12), and uPA (n = 16), peripheral serum was used for isolation of total RNA, library preparation, and NGS sequencing to achieve a comparative analysis of miRNA expression. Five-fold cross-validation support vector machine learning (ML) models were employed to search for miRNA that could be used as markers of PA and its forms.Results: In our cohort of patients, the discovered combinations of miRNAs could, with a high level of accuracy, sensitivity, and specificity, characterize the difference between HT and PA, as well as between a combined group of HT + bPA vs. uPA. The differentiating parameters were moderately good for comparison of bPA vs. uPA. Conclusion: Within our patient cohort, and using ML, the study identified distinctly different miRNA profiles between HT and PA, as well as between bPA and uPA. Further validation studies may lead to the emergence of a new tool for clinical diagnostics of PA.

    Keywords: hyperaldosteronism1, hypertension2, MicroRNAs3, genetic markers4, machine learning5, Serum6

    Received: 14 Oct 2024; Accepted: 28 Feb 2025.

    Copyright: © 2025 Makhnov, Axling, Barazeghi, Stålberg, Åkerström and Hellman. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Nikita Makhnov, Uppsala University, Uppsala, Sweden

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

    Research integrity at Frontiers

    Man ultramarathon runner in the mountains he trains at sunset

    94% of researchers rate our articles as excellent or good

    Learn more about the work of our research integrity team to safeguard the quality of each article we publish.


    Find out more